Pharmachronicles

Top Menu

  • Home
  • Our Blog
  • Contact Us

Main Menu

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
Sign in / Join

Login

Welcome! Login in to your account
Lost your password?

Lost Password

Back to login
  • Home
  • Our Blog
  • Contact Us

Pharmachronicles

Header Banner

Pharmachronicles

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
  • UGC-Cancelled-List of journals

  • NAAC stops accepting applications for accreditation from pharmacy colleges

  • Pursuing MPhil/PhD while working as a teacher will effect experience: UGC

  • Public notice by government of india ministry of health and family welfare

Medical & Health
Home›Medical & Health›Propitious results from the new Alzheimer’s Drug.

Propitious results from the new Alzheimer’s Drug.

By Ramoju kishore kumar
August 2, 2018
807
0
Share:

A new hope to fight against Alzheimer’s disease, which is from a phase 2 clinical trial show that the medication, an antibody called BAN2401, slowed the progression of the disease and increased cognitive performance.

BAN2401 is produced by the Biogen and Eisai presented details about the clinical trial in July 25, 2018, at the Alzheimer’s Association International Conference in Chicago.

The trial involved 856 patients with mild cognitive impairment related to Alzheimer’s, who were divided into six groups. Five groups of patients were given various doses of the drug, and one group was given a placebo. The study assessed changes over 18 months by looking at levels of amyloid in the brain. Alzheimer’s patients have abnormal levels of the amyloid proteins that can clump together to form plaques. These plaques collect between neurons and disrupt cell function, according to the National Institute on Aging.

The study also used three common cognitive assessments for Alzheimer’s and dementia to determine changes in brain functioning.

At its highest dose, the drug reduced amyloid proteins as much as 93 percent. The trial also reported a 26 to 30 percent improvement in cognition.

Amyloids and Alzheimer’s

“This is the first late-stage anti-amyloid antibody study to successfully achieve statistically significant results at 18 months, further validating the amyloid hypothesis,” said Lynn Kramer, MD, chief clinical officer and chief medical officer of Eisai’s neurology business group.

“Overall, these findings are very exciting,” says Daniel Kaufer, MD, director of the memory disorders program at the University of North Carolina in Chapel Hill. “In this population, the treatment was able to reduce amyloids in people’s brains, and that that was correlated with clinical improvement in slowing people’s decline over 12 to 18 months.” he says.

Dr. Kaufer emphasizes that the clinically significant effects of the treatment correlated with the dose. “The higher the dose of treatment, the greater reduction in amyloid and the greater the clinical effect,” he says. “When you’re evaluating any treatment, that association is a very reassuring sign.”

Kaufer points out that one aspect of the trial’s design makes its findings a little more difficult to compare to a conventional study design. Rather than randomly distribute patients into six groups, the researchers used something called a Bayesian adaptive randomization design. “That means that as they enrolled new subjects in the study, they first looked at preliminary outcomes. They used that information to modify how they enrolled future subjects in the study,” says Kaufer. He adds that the approach makes it harder to speculate how these findings will translate into a real-world clinical practice.

Future Expectations

But Kaufer is cautiously optimistic, and he expects that a phase 3 trial will provide answers to lingering questions. “Is it going to work? Is it going to be safe?” he asks. “Until those results, you really can’t say anything definitive about the treatment,” he adds.

The conclusion of that trial, as well as any potential approval by the Food and Drug Administration, are still two or more years away. “Part of the problem is that these studies take a long time,” Kaufer says. “The outcomes in this study were evaluated at 12 to 18 months. Even before that begins, it takes at least six months to enroll people in the study.”

TagsAlzheimer’sAmyloidsclinical trial
Previous Article

“RANIPILL”- A MINI SWALLOWABLE AUTO INJECTOR WITH ...

Next Article

Failure of the immunotherapy agent in the ...

0
Shares
  • 0
  • +
  • 0
  • 0
  • 0
  • 0
Avatar photo

Ramoju kishore kumar

Related articles More from author

  • Phama news

    Drug Discovery and development process for Alzheimer’s disease

    January 31, 2020
    By Ramoju kishore kumar
  • FDA AlertsMedical & HealthMedical research

    FDA approves a new clinical trial for non-healing wounds.

    October 28, 2017
    By admin
  • Medical & Health

    ALZHEIMER’S DISEASE- UNOFFICIALLY THE “TYPE 3 DIABETES”

    September 9, 2018
    By susmitha.arepalli
  • DiseaseMedical & HealthMedical researchTreatment

    Can Psoriasis increase the risk of Type 2 Diabetes

    November 25, 2018
    By Ramoju kishore kumar
  • DiseaseMedical & HealthMedical researchTreatment

    Excess weight and body fat cause cardiovascular disease

    June 18, 2019
    By Ramoju kishore kumar
  • Medical & Health

    Good Sleep, cheerful Mood can Stay Sharper In Old Age

    February 15, 2020
    By Sriram Nagarajan

Leave a reply Cancel reply

You may interested

  • Phama news

    ARRYTHMIAS

  • Phama news

    ORAL CONTRACEPTIVES

  • BLOGS

    Spinal Cord Epidural Stimulation A Breakthrough Treatment Restores Voluntary Movement to Paralyzed Man’s Legs

  • LATEST REVIEWS

  • TOP REVIEWS

  • Pharmacists are not eligible for certificate program of community health

    0
  • A New Class of Antimicrobials Has Just Been Found in Human Breast Milk Fresh super ...

    0

Timeline

  • May 24, 2021

    LIST OF SCOPUS INDEXED JOURNALS APRIL 2021

  • October 20, 2020

    List of UGC Approved journals 2020

  • June 8, 2020

    Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

  • June 4, 2020

    UGC-Cancelled-List of journals

  • June 1, 2020

    Saroj Group Of Hospitals restarts its complete operations – see major footfall in OPD consultation

Latest Comments

  • Sowmya V
    on
    December 13, 2019
    Nice keep it up

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

Find us on Facebook

Follow Us on Instagram

logo

Dui viverra Faucibus aliquet quis phasellus accumsan. Donec et facilisis sociosqu sed tortor elit eu aliquid turpis ridiculus.

Fly, shall, have greater fifth spirit midst under from stars thing is, had creepeth multiply kind. Man may they’re meat years have third bring replenish air two light deep fill.

About us

  • Dr.N.Sriram, Founder CEO, Pharmachronicles, HITS college of Pharmacy, Ghatkesar, Hyderabad, India
  • 9704361947
  • pharmachronicles@gmail.com
  • Recent

  • Popular

  • Comments

  • LIST OF SCOPUS INDEXED JOURNALS APRIL 2021

    By admin
    May 24, 2021
  • List of UGC Approved journals 2020

    By admin
    October 20, 2020
  • Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

    By Sriram Nagarajan
    June 8, 2020
  • UGC-Cancelled-List of journals

    By admin
    June 4, 2020
  • Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    By Sundari srinidhi
    December 12, 2019
  • FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    By admin
    July 16, 2015
  • Record Numbers of FDA‑Approved Drugs: Recent Trends

    By admin
    July 16, 2015
  • There make for Sixth that multiply blessed two divide creeping

    By admin
    July 16, 2015
  • Sowmya V
    on
    December 13, 2019

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    Nice keep it up

Photostream

    Follow us

    • Contact
    • STUDENTS ZONE
    • About Us
    © Copyright Pharmachronicles. All rights reserved.